Detecting the Presence of Anti-HLA Antıbodies in Autoimmune Diseases

Abstract

Aim: By creating antibodies, the immune system protects the body from foreign antigens. The immune system may occasionally sustain damage that results in a loss of tolerance to its antigens, which triggers the creation of antibodies directed against those antigens. Another challenge in solid organ transplantation is the existence of these anti-HLA antibodies. Our goal was to find out if common autoimmune disorders such type 1 diabetes (T1D), Behçet's disease (BD), and ankylosing spondylitis (AS) result in the development of anti-HLA antibodies. Materials and Methods: 100 patients with AS, 100 patients with BD, 60 patients with T1D, and 100 healthy people were included in this study. PRA screening tests were performed on serum from blood samples taken from both patients and healthy individuals to look for the presence of anti-HLA antibodies. Results: Of the AS patients, 5 were positive for PRA class II alone, 7 were positive for both PRA class I and class II, and 1 patient was positive for PRA class I. In BD, 3 patients was positive for both PRA class I and II, 7 patients was positive for PRA class II alone, and 1 patient was positive for PRA class I. In T1D, 1 patient were positive for PRA class I, 3 patients were positive for PRA class II alone, and 2 patients were positive for both. In summary: When three patient groups were compared with the control group, there was no statistically significant difference in the detection of anti-HLA antibodies between the patient groups and the control group.

Keywords

• Ankylosing spondylitis
• behçet’s disease
• type 1 diabetes
• transplantation
• PRA

References

1. Abbas A, Lichtman A, Pillai S. Cellular and Molecular Immunology E-Book. Elsevier Health Sciences, 2014.
2. Rosenbaum ER, Pandey S, Harville TO, Drobena GA, Cottler-Fox M. Flow cytometric panel-reactive antibody results and the ability to find transfusion-compatible platelets after antibody-desensitization for allogeneic bone marrow transplant. Ann Clin Lab Sci. 2016; 46:662-65.
3. Steggerda JA, Kang A, Pan SH. Outcomes of highly sensitized patients undergoing simultaneous liver and kidney transplantation: a single-center experience with desensitization. Transplantation Proceedings. 2017; 49(6):1394-401.
4. Moll JM, Haslock I, Macrae IF, Wright V. Associations between ankylosing spondylitis, psoriatic arthritis, Reiter’s disease, the intestinal arthropathies, and Behçet’s syndrome. Medicine. 1974; 53(5):343-64.
5. Sakane T, Takeno M, Suzuki N, Inaba G. Behçet’s disease. New Eng J Med. 1999; 341:1284-91.
6. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet’s disease. Arch Ophthalmol. 1982; 100:1455-58.
7. Fueyo-Díaz R, Magallón-Botaya R, Masluk B, et al. Prevalence of celiac disease in primary care: the need for its own code. BMC Health Serv Res. 2019; 19:578.
8. Del Angel-Pablo AD, Buendía-Roldán I, Mejía M, et al. Anti-HLA class II antibodies correlate with C-reactive protein levels in patients with rheumatoid arthritis associated with interstitial lung disease. Cells. 2020; 9:691.

9. Jackman RP, Cruz GI , Nititham J, et al. Increased alloreactive and autoreactive antihuman leucocyte antigen antibodies associated with systemic lupus erythematosus and rheumatoid arthritis. Lupus Sci Med. 2018; 5:e000278.
10. Nicknam MH, Mahmoudi M, Amirzargar AA, et al. Determination of HLA-B27 subtypes in Iranian patients with ankylosing spondylitis. Iran J Allergy Asthma Immunol. 2008; 7(1):19-24.
11. Mou Y, Zhang P, Li Q, et al. Clinical features in juvenile-onset ankylosing spondylitis patients carrying different B27 subtypes. Biomed Res Int. 2015; 2015: 594878.
12. Mou Y, Wu Z, Gu J, et al. HLA‐B27 polymorphism in patients with juvenile and adult‐onset ankylosing spondylitis in Southern China. Tissue Antigens. 2010; 75: 56-60.
13. Yang T, Duan Z, Wu S, et al. Association of HLA-B27 genetic polymorphisms with ankylosing spondylitis susceptibility worldwide: a meta-analysis. Mod Rheumatol. 2014; 24:150-61.
14. Diyarbakir E, Eyerci N, Melikoglu M, Topcu A, Pirim I. HLA B27 subtype distribution among patients with ankylosing spondylitis in eastern Turkey. Genet Test Mol Biomarkers. 2012; 16:456-58.
15. Evereklioglu C. Current concepts in the etiology and treatment of Behçet’s disease. Surv Ophthalmol. 2005; 50:297-50.
16. Wechsler B, Du-Boutin LTH. Interféron et maladie de Behçet. Rev Med Interne. 2002; 23:495S-499S.
17. Park SH, Park KS, Seo YI, et al. Association of MICA polymorphism with HLA-B51 and disease severity in Korean patients with Behcet’s disease. J Korean Med Sci. 2002; 17: 366-70.
18. Montes-Cano MA, Conde-Jaldón M, García-Lozano JR, et al. HLA and non-HLA genes in Behçet’s disease: a multicentric study in the Spanish population. Arthritis Res Ther. 2013; 15(5): 145.
19. Takeuchi M, Ombrello MJ, Kirino Y, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet’s disease in HLA-B* 51 carriers. Ann Rheum Dis. 2016; 75:2208-211.
20. Gouda W, Mageed L, Abd El Dayem SM, Ashour E, Afify M. Evaluation of pro-inflammatory and anti-inflammatory cytokines in type 1 diabetes mellitus. Bull Natl Res Cent. 2018; 42:1-6.
21. Schipper RF, Koeleman BPC, Bruining GJ, et al. HLA class II associations with Type 1 diabetes mellitus: a multivariate approach. Tissue Antigens. 2001; 57:144-150.
22. Mosaad YM, Auf FA, Metwally SS, et al. HLA-DQB1* alleles and genetic susceptibility to type 1 diabetes mellitus. World J Diabetes. 2012; 3:149-55.